Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.

BMC Health Services Research
Elisabeth FenwickGraham Nichol

Abstract

The cost-effectiveness acceptability curve (CEAC) is a method for summarizing the uncertainty in estimates of cost-effectiveness. The CEAC, derived from the joint distribution of costs and effects, illustrates the (Bayesian) probability that the data are consistent with a true cost-effectiveness ratio falling below a specified ceiling ratio. The objective of the paper is to illustrate how to construct and interpret a CEAC. A retrospective cost-effectiveness analysis of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) randomized controlled trial with 4060 patients followed for 3.5 years. The target population was patients with atrial fibrillation who were 65 years of age or had other risk factors for stroke or death similar to those enrolled in AFFIRM. The intervention involved the management of patients with atrial fibrillation with antiarrhythmic drugs (rhythm-control) compared with drugs that control heart rate (rate-control). Measurements of mean survival, mean costs and incremental cost-effectiveness were made. The uncertainty surrounding the estimates of cost-effectiveness was illustrated through a cost-effectiveness acceptability curve. The base case point estimate for the difference in effect...Continue Reading

References

Jul 1, 1990·Medical Decision Making : an International Journal of the Society for Medical Decision Making·W C Black
Sep 1, 1994·Health Economics·B A van HoutF F Rutten
May 5, 1998·Medical Decision Making : an International Journal of the Society for Medical Decision Making·A A Stinnett, J Mullahy
Jan 23, 1999·Medical Decision Making : an International Journal of the Society for Medical Decision Making·D F HeitjanW Whang
Sep 3, 1999·BMJ : British Medical Journal·A H Briggs, A M Gray
Sep 27, 2002·The New England Journal of Medicine·Braden J MannsCam Donaldson
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
May 22, 2003·The New England Journal of Medicine·Scott D RamseyUNKNOWN National Emphysema Treatment Trial Research Group
May 6, 2004·Health Economics·Elisabeth FenwickAndrew Briggs
Nov 3, 2004·Annals of Internal Medicine·Deborah A MarshallUNKNOWN AFFIRM and CORE Investigators
Nov 3, 2004·Annals of Internal Medicine·Tristram D Bahnson, Augustus O Grant

❮ Previous
Next ❯

Citations

Oct 8, 2008·Archives of General Psychiatry·Gary A ZarkinUNKNOWN COMBINE Cost-Effectiveness Research Group
Oct 19, 2007·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Xin Sun, Thomas Faunce
Aug 27, 2013·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Elise Chia-Hui TanMing-Chin Yang
Feb 28, 2013·PharmacoEconomics·Bernd BrüggenjürgenStefan N Willich
Aug 1, 2012·Biosecurity and Bioterrorism : Biodefense Strategy, Practice, and Science·Demetrios N KyriacouBrian P Schmitt
Dec 1, 2012·Journal of the National Cancer Institute·Ajay S BehlMichael V Maciosek
May 26, 2012·BMC Public Health·Tracy L Kolbe-AlexanderWillem Van Mechelen
Dec 12, 2012·Bulletin of the World Health Organization·Christine ButtorffVikram Patel
May 24, 2014·Journal of Occupational and Environmental Medicine·Johanna M van DongenJudith E Bosmans
Jun 4, 2013·Advances in Health Sciences Education : Theory and Practice·Wanrudee IsaranuwatchaiAdam Dubrowski
Jun 3, 2014·Neurosurgical Focus·Matthew D AlvinThomas E Mroz
Jun 15, 2014·BMC Cardiovascular Disorders·Anil VaidyaErik A L Biessen
Sep 26, 2013·Acta Oncologica·Corina J van den HurkJan W Coebergh
Mar 13, 2014·Journal of Biopharmaceutical Statistics·Heejung Bang, Hongwei Zhao
Mar 14, 2013·The Laryngoscope·Luke Rudmik, Michael Drummond
Nov 26, 2014·Journal of Surgical Oncology·Nicole J Look HongKelvin Chan
Feb 26, 2008·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Josh J CarlsonDavid L Veenstra
Apr 16, 2016·Clinical Oral Implants Research·Charlotte JensenMarco S Cune

❮ Previous
Next ❯

Software Mentioned

AFFIRM

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.